Research Article
Potential Target Antigens for a Universal Vaccine in Epithelial Ovarian Cancer
Table 6
Coexpression of MHC class I components with tumorantigens.
| | | | | | NY-ESO | | | n = 80 | n = 116 | n = 152 | n = 89 | n = 20 | n = 173 | | n/total (%) | n/total (%) | n/total (%) | n/total (%) | n/total (%) | n/total (%) |
| HLA- | 52/80 | 64/116 | 80/152 | 50/89 | 13/20 | 96/173 | n = 98 | (65.0) | (55.2) | (52.6) | (56.2) | (65.0) | (55.0) | HLA-B/ | 62/78 | 94/116 | 111/151 | 67/89 | 15/20 | 129/171 | n = 136 | (79.5) | (81.0) | (73.5) | (75.3) | (75.0) | (75.4) | MHC class | 66/80 | 96/116 | 117/152 | 72/89 | 16/20 | 136/173 | n = 143 | (82.5) | (82.8) | (77.0) | (80.9) | (80.0) | (78.4) | All | 66/174 | 96/178 | 117/169 | 72/167 | 16/175 | 136/183 | n = 183 | (37.9) | (53.9) | (69.2) | (43.1) | (9.1) | (74.3) |
|
|
and MHC class in all subgroup patients (n = 183); tumorantigen expression.
|